Table 2. Univariate and multivariable analysis of prognostic factors for the entire population (n = 416).
| Variables | Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|
| n = 416 (%) | p value | RR | 95% CI | p value | |
| Sex | 0.374 | ||||
| Female | 129 (31.0) | ||||
| Male | 287 (69.0) | ||||
| Age (years) | 0.153 | ||||
| <65 | 281 (67.5) | ||||
| ≥65 | 135 (32.5) | ||||
| Tumor size (cm) | 0.019 | 1.474 | 1.051-2.065 | 0.024 | |
| <4 | 81 (19.5) | ||||
| ≥4 | 335 (80.5) | ||||
| Macroscopic type | 0.298 | ||||
| Borrmann 1 | 9 (2.2) | ||||
| Borrmann 2 | 70 (16.8) | ||||
| Borrmann 3 | 316 (76.0) | ||||
| Borrmann 4 | 21 (5.0) | ||||
| Histological grade | 0.999 | ||||
| Well differentiated | 126 (30.3) | ||||
| Moderately differentiated | 86 (20.7) | ||||
| Poorly differentiated | 189 (45.4) | ||||
| Undifferentiated | 15 (3.6) | ||||
| Venous invasion | 0.301 | ||||
| Negative | 410 (98.6) | ||||
| Positive | 6 (1.4) | ||||
| Lymphatic vessels invasion | 0.002 | ||||
| Negative | 334 (80.3) | ||||
| Positive | 82 (19.7) | ||||
| Margin status | 0.755 | ||||
| Negative | 407 (97.8) | ||||
| Positive | 9 (2.2) | ||||
| pT stage | 0.002 | 1.260 | 1.057–1.502 | 0.010 | |
| pT2 | 75 (18.0) | ||||
| pT3 | 187 (45.0) | ||||
| pT4 | 154 (37.0) | ||||
| pN stage | <0.001 | 1.187 | 1.028–1.370 | 0.020 | |
| pN0 | 56 (13.5) | ||||
| pN1 | 122 (29.3) | ||||
| pN2 | 126 (30.3) | ||||
| pN3 | 112 (26.9) | ||||
| TNM stage | 0.001 | ||||
| Stage II | 253 (60.8) | ||||
| Stage III | 163 (39.2) | ||||
| Lymphadenectomy | 0.776 | ||||
| D2 | 287 (69.0) | ||||
| D2+ | 129 (31.0) | ||||
| Number of LNs retrieved | 0.578 | ||||
| Inadequate (n<15) | 142 (34.1) | ||||
| Adequate (n ≥ 15) | 274 (65.9) | ||||
| Locoregional recurrence | <0.001 | 2.383 | 1.545–3.676 | <0.001 | |
| Absent | 315 (75.7) | ||||
| Present | 101 (24.3) | ||||
| Distant recurrence | <0.001 | 2.346 | 1.563–3.521 | <0.001 | |
| Absent | 275 (66.1) | ||||
| Present | 141 (33.9) | ||||
n, number of patients; LNs, lymph nodes; RR, relative risk; 95% CI, 95% confidence interval.